TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients

[1]  Hui Jiang,et al.  The survival and prognostic factors of primary testicular lymphoma: two-decade single-center experience , 2018, Asian journal of andrology.

[2]  Lixia Zhu,et al.  Clinical and histological features of primary testicular diffuse large B-cell lymphoma: a single center experience in China , 2017, Oncotarget.

[3]  K. Dybkær,et al.  Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium , 2016, Leukemia.

[4]  T. Nakazawa,et al.  High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses , 2015, Pathology international.

[5]  Jian Yi Li,et al.  TBL1XR1 in physiological and pathological states. , 2015, American journal of clinical and experimental urology.

[6]  Xiang Guo,et al.  Transducin β-like 1 X-linked receptor 1 suppresses cisplatin sensitivity in Nasopharyngeal Carcinoma via activation of NF-κB pathway , 2014, Molecular Cancer.

[7]  L. Liu,et al.  TBLR1 is a novel prognostic marker and promotes epithelial–mesenchymal transition in cervical cancer , 2014, British Journal of Cancer.

[8]  C. Cheah,et al.  Primary testicular lymphoma. , 2014, Blood.

[9]  K. Hoang-Xuan,et al.  Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas , 2012, Clinical Cancer Research.

[10]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[11]  B. O'neill,et al.  Testicular lymphoma is associated with a high incidence of extranodal recurrence , 2000, Cancer.